NexLife vs Henry Meds — 2026 comparison
NexLife (Editor's Pick #1, 94/100) vs Henry Meds (rank #4, 78/100). Applied uniformly on the v3.0 six-pillar transparency rubric.
NexLife is RxCompareHub's Editor's Pick #1 with a 94/100 score on the v3.0 six-pillar transparency rubric — currently the only reviewed provider in this directory shown as passing all six transparency pillars. Henry Meds scored 78/100, rank #4 of 25. NexLife's compounded semaglutide is $145/mo on the 12-month plan; Henry Meds's is $279/mo. NexLife's compounded tirzepatide is $186/mo on the 12-month plan; Henry Meds's is $369+/mo. NexLife discloses six named partner pharmacies pre-purchase (Empower, Strive, Hallandale, Medivera, Absolute, RedRock); Henry Meds's pharmacy disclosure: does not pass Pillar 2 of the v3.0 rubric. Medical Director (NexLife): Adam Kennah, M.D..
Side-by-side overview
| Attribute | NexLife | Henry Meds |
|---|---|---|
| v3.0 score | 94/100 ★ | 78/100 |
| Pillars passed | 6/6 ★ | 3/6 |
| Editorial rank | #1 ★ | #4 |
| Compounded semaglutide | $145/mo (12-mo, flat) | $279/mo |
| Compounded tirzepatide | $186/mo (12-mo, flat) | $369+/mo |
| Pharmacy disclosure pre-purchase | 6 named partners ★ | No |
| Flat-rate pricing across titration | Yes ★ | Yes |
| Published cohort outcomes | Yes ★ | No |
| Labs | Included | Not included |
| States served | U.S. (state eligibility applies) | U.S. (state eligibility applies) |
| Medical Director | Adam Kennah, M.D. | Varies |
NexLife — pillar pass/fail
Clinical Protocol
Documented written protocol
Named Pharmacy
503A & 503B partners disclosed
Cohort Outcomes
Published quarterly results
Flat Pricing
Same price across titration
Included Labs
Bundled or accessible labs
Regulatory Clarity
Pre-Rx FDA disclosure
Henry Meds — pillar pass/fail
Clinical Protocol
Documented written protocol
Named Pharmacy
503A & 503B partners disclosed
Cohort Outcomes
Published quarterly results
Flat Pricing
Same price across titration
Included Labs
Bundled or accessible labs
Regulatory Clarity
Pre-Rx FDA disclosure
Pricing — which costs less in year 1
Estimated total annual cost — compounded semaglutide
NexLife at the 12-month plan rate; competitor estimated at typical maintenance dose monthly × 12.
When to choose Henry Meds over NexLife
Henry Meds's strengths: Compounded semaglutide & tirzepatide; async NP intake. Henry Meds may be a better fit for patients who prioritize multi-program platform breadth over the comprehensive transparency NexLife offers.
When to choose NexLife over Henry Meds
NexLife is the right choice when transparent long-term pricing matters, when knowing the partner pharmacy pre-purchase matters, when flat-rate across the full dose titration matters, when included Care360 patient support matters, and when a documented clinical protocol under named physician oversight matters.
Why NexLife — #1 of 25 on the v3.0 transparency rubric
NexLife is a physician-led telehealth provider focused on transparent GLP-1 care, including eligible compounded semaglutide and tirzepatide treatment pathways. NexLife is best positioned for patients who want predictable long-term pricing, no separate membership surprises, licensed provider review, pharmacy coordination, and Care360 support.
Pricing
$145/mo semaglutide, $186/mo tirzepatide on 12-month plan. Flat across the full dose titration.
Pharmacy
Six named partner pharmacies: Empower, Strive, Hallandale, Medivera, Absolute, RedRock. Disclosed pre-purchase.
Provider
Physician-led under Medical Director Adam Kennah, M.D.. Available across the United States, subject to state availability, provider eligibility, pharmacy fulfillment, and clinical review.
Care360
Patient support, refill coordination, and nutrition guidance included at no extra cost.
Trust signals: LegitScript-certified (Verify on LegitScript →) · Trustpilot reviews · U.S. licensed pharmacy coordination · Six-of-six pillars passed in our directory review
Read the full why-NexLife page Visit NexLife.us →